Terns Pharmaceuticals

TERN45

$7.81arrow_drop_up4.69%$0.35

TERN45

$7.81

arrow_drop_up4.69%$0.35

Performance History

Key Stats
Open	$7.60
Prev. Close	$7.46
EPS	-1.32
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	7.03	7.99
52 Week Range	3.26	10.03

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.32

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals, Inc. (TERN) is a biopharmaceutical company focused on discovering and developing innovative therapies to treat liver diseases and cancer. The company's mission is to improve the lives of patients suffering from these debilitating conditions. TERN stock price history shows the company's growth and success over the years.

Terns Pharmaceuticals, Inc. is committed to providing high-quality healthcare solutions for patients in need. The company's dedication to research and development has led to the development of numerous novel drug candidates, which are currently in various stages of clinical trials. With its strong portfolio of drug candidates, TERN is well-positioned to address the significant unmet medical needs in liver diseases and cancer.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO
Headquarters: Foster City
Employees: 46
Exchange: NASDAQ

Keep an eye on Terns Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the 52-week high and low for Terns Pharmaceuticals (TERN)?

For Terns Pharmaceuticals (TERN), the 52-week high is $10.03, which is 28.43% from the current price. The 52-week low is $3.26, the current price is 139.57% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is Terns Pharmaceuticals's (TERN) price per share?

The current price per share for Terns Pharmaceuticals (TERN) is $7.81. The stock has seen a price change of $0.35 recently, indicating a 4.69% change. This reflects the stock's recent market performance and investor sentiment.

help

Is Terns Pharmaceuticals (TERN) a growth stock?

Terns Pharmaceuticals (TERN) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Terns Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Terns Pharmaceuticals (TERN) stock price performance year to date (YTD)?

As of the latest data, Terns Pharmaceuticals (TERN) has a year-to-date price change of 20.52%. Over the past month, the stock has experienced a price change of 9.69%. Over the last three months, the change has been 7.28%. Over the past six months, the figure is -4.64%.

help

Is Terns Pharmaceuticals (TERN) a profitable company?

Terns Pharmaceuticals (TERN) has a net income of -$90.21M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$102.56M. Furthermore, the EBITDA is -$107.91M.

help

What is the market capitalization of Terns Pharmaceuticals (TERN)?

Terns Pharmaceuticals (TERN) has a market capitalization of $549.6M. The average daily trading volume is 855.64K, indicating the stock's liquidity and investor engagement.

News

WEIGHT-LOSS DRUGS

ALTIMMUNE

TERNS PHARMACEUTICALS

ELI LILLY

NOVO NORDISK

7/20/2024

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? - The Motley Fool

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

CALENDAR OF EVENTS

CONFERENCE CALLS/ WEBCASTS

CLINICAL STUDY

6/21/2024

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation